Medulloblastoma stem cells: Modeling tumor heterogeneity

Cancer Letters

Volumn 338, Issue 1, 2013, Pages 23-31

  Manoranjan, Branavan ^a,b   Venugopal, Chitra ^a   McFarlane, Nicole ^a   Doble, Bradley W ^a,b   Dunn, Sandra E ^c   Scheinemann, Katrin ^d   Singh, Sheila K ^a,b,d  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d MCMASTER CHILDREN S HOSPITAL   (Canada)

Author keywords

Brain tumor initiating cells; Cancer stem cell; Medulloblastoma; Signaling pathways

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; SONIC HEDGEHOG PROTEIN; WNT PROTEIN;

BRAIN DEVELOPMENT; CANCER STEM CELL; CARCINOGENESIS; CELL HETEROGENEITY; CELL POPULATION; CELL PROLIFERATION; CELL RENEWAL; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; MEDULLOBLASTOMA; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 84882833929     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.07.010     Document Type: Review

References (72)

1. Wright J. Neurocytoma or neuroblastoma, a kind of tumor not generally recognized. J. Exp. Med. 1910, 12:556-561.
2. Bailey P., Cushing H. Medulloblastoma cerebelli: a common type of midcerebellar glioma of childhood. Arch. Neurol. Psychiatry 1925, 14:192-224.
3. Cho Y.J., Tsherniak A., Tamayo P., Santagata S., Ligon A., Greulich H., Berhoukim R., Amani V., Goumnerova L., Eberhart C.G., Lau C.C., Olson J.M., Gilbertson R.J., Gajjar A., Delattre O., Kool M., Ligon K., Meyerson M., Mesirov J.P., Pomeroy S.L. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J. Clin. Oncol. 2011, 29:1424-1430.
4. Kool M., Koster J., Bunt J., Hasselt N.E., Lakeman A., van Sluis P., Troost D., Meeteren N.S.-v., Caron H.N., Cloos J., Mršić A., Ylstra B., Grajkowska W., Hartmann W., Pietsch T., Ellison D., Clifford S.C., Versteeg R. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS ONE 2008, 3:e3088.
5. Northcott P.A., Korshunov A., Witt H., Hielscher T., Eberhart C.G., Mack S., Bouffet E., Clifford S.C., Hawkins C.E., French P., Rutka J.T., Pfister S., Taylor M.D. Medulloblastoma comprises four distinct molecular variants. J. Clin. Oncol. 2011, 29:1408-1414.
6. Pomeroy S.L., Tamayo P., Gaasenbeek M., Sturla L.M., Angelo M., McLaughlin M.E., Kim J.Y.H., Goumnerova L.C., Black P.M., Lau C., Allen J.C., Zagzag D., Olson J.M., Curran T., Wetmore C., Biegel J.A., Poggio T., Mukherjee S., Rifkin R., Califano A., Stolovitzky G., Louis D.N., Mesirov J.P., Lander E.S., Golub T.R. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002, 415:436-442.
7. Thompson M.C., Fuller C., Hogg T.L., Dalton J., Finkelstein D., Lau C.C., Chintagumpala M., Adesina A., Ashley D.M., Kellie S.J., Taylor M.D., Curran T., Gajjar A., Gilbertson R.J. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J. Clin. Oncol. 2006, 24:1924-1931.
8. Kool M., Korshunov A., Remke M., Jones D.T., Schlanstein M., Northcott P.A., Cho Y.J., Koster J., Schouten-van Meeteren A., van Vuurden D., Clifford S.C., Pietsch T., von Bueren A.O., Rutkowski S., McCabe M., Collins V.P., Backlund M.L., Haberler C., Bourdeaut F., Delattre O., Doz F., Ellison D.W., Gilbertson R.J., Pomeroy S.L., Taylor M.D., Lichter P., Pfister S.M. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 2012, 123:473-484.
9. Taylor M.D., Northcott P.A., Korshunov A., Remke M., Cho Y.J., Clifford S.C., Eberhart C.G., Parsons D.W., Rutkowski S., Gajjar A., Ellison D.W., Lichter P., Gilbertson R.J., Pomeroy S.L., Kool M., Pfister S.M. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012, 123:465-472.
10. Pei Y., Moore C.E., Wang J., Tewari A.K., Eroshkin A., Cho Y.J., Witt H., Korshunov A., Read T.A., Sun J.L., Schmitt E.M., Miller C.R., Buckley A.F., McLendon R.E., Westbrook T.F., Northcott P.A., Taylor M.D., Pfister S.M., Febbo P.G., Wechsler-Reya R.J. An animal model of MYC-driven medulloblastoma. Cancer Cell 2012, 21:155-167.
11. Gibson P., Tong Y., Robinson G., Thompson M.C., Currle D.S., Eden C., Kranenburg T.A., Hogg T., Poppleton H., Martin J., Finkelstein D., Pounds S., Weiss A., Patay Z., Scoggins M., Ogg R., Pei Y., Yang Z.-J., Brun S., Lee Y., Zindy F., Lindsey J.C., Taketo M.M., Boop F.A., Sanford R.A., Gajjar A., Clifford S.C., Roussel M.F., McKinnon P.J., Gutmann D.H., Ellison D.W., Wechsler-Reya R., Gilbertson R.J. Subtypes of medulloblastoma have distinct developmental origins. Nature 2010, 468:1095-1099.
12. Kawauchi D., Robinson G., Uziel T., Gibson P., Rehg J., Gao C., Finkelstein D., Qu C., Pounds S., Ellison D.W., Gilbertson R.J., Roussel M.F. A mouse model of the most aggressive subgroup of human medulloblastoma. Cancer Cell 2012, 21:168-180.
13. Wang V.Y. Genetic regulation of cerebellar development. Nat. Rev. Neurosci. 2001, 2:484-491.
14. Sotelo C. Cellular and genetic regulation of the development of the cerebellar system. Prog. Neurobiol. 2004, 72:295-339.
15. Lee A., Kessler J.D., Read T.-A., Kaiser C., Corbeil D., Huttner W.B., Johnson J.E., Wechsler-Reya R.J. Isolation of neural stem cells from the postnatal cerebellum. Nat. Neurosci. 2005, 8:723-729.
16. Fink A.J., Englund C., Daza R.A., Pham D., Lau C., Nivison M., Kowalczyk T., Hevner R.F. Development of the deep cerebellar nuclei: transcription factors and cell migration from the rhombic lip. J. Neurosci. 2006, 26:3066-3076.
17. Wang V.Y., Rose M.F., Zoghbi H.Y. Math1 expression redefines the rhombic lip derivatives and reveals novel lineages within the brainstem and cerebellum. Neuron 2005, 48:31-43.
18. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., Scheithauer B.W., Kleihues P. The WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114(2007):97-109.
19. Yokota N., Aruga J., Takai S., Yamada K., Hamazaki M., Iwase T., Sugimura H., Mikoshiba K. Predominant expression of human zic in cerebellar granule cell lineage and medulloblastoma. Cancer Res. 1996, 56:377-383.
20. Salsano E., Paterra R., Figus M., Menghi F., Maderna E., Pollo B., Solero C.L., Massimi L., Finocchiaro G. Expression profile of frizzled receptors in human medulloblastomas. J. Neurooncol. 2012, 106:217-280.
21. Katsetos C.D., Herman M.M., Krishna L., Vender J.R., Vinores S.A., Agamanolis D.P., Schiffer D., Burger P.C., Urich H. Calbindin-D28k in subsets of medulloblastomas and in the human medulloblastoma cell line D283 Med. Arch. Pathol. Lab. Med. 1995, 119:734-743.
22. Kumanishi T., Washiyama K., Watabe K., Sekiguchi K. Glial fibrillary acidic protein in medulloblastomas. Acta Neuropathol. 1985, 67:1-5.
23. Kho A.T., Zhao Q., Cai Z., Butte A.J., Kim J.Y., Pomeroy S.L., Rowitch D.H., Kohane I.S. Conserved mechanisms across development and tumorigenesis revealed by a mouse development perspective of human cancers. Genes Dev. 2004, 18:629-640.
24. Lee Y., Miller H.L., Jensen P., Hernan R., Connelly M., Wetmore C., Zindy F., Roussel M.F., Curran T., Gilbertson R.J., McKinnon P.J. A molecular fingerprint for medulloblastoma. Cancer Res. 2003, 63:5428-5437.
25. Hemmati H.D., Nakano I., Lazareff J.A., Masterman-Smith M., Geschwind D.H., Bronner-Fraser M., Kornblum H.I. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl. Acad. Sci. USA 2003, 100:15178-15183.
26. Clifford S.C., Lusher M.E., Lindsey J.C., Langdon J.A., Gilbertson R.J., Straughton D., Ellison D.W. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle 2006, 5:2666-2670.
27. Ellison D.W., Onilude O.E., Lindsey J.C., Lusher M.E., Weston C.L., Taylor R.E., Pearson A.D., Clifford S.C. United Kingdom Children's Cancer Study Group Brain Tumour Committee, beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J. Clin. Oncol. 2005, 23:7951-7957.
28. Fattet S., Haberler C., Legoix P., Varlet P., Lellouch-Tubiana A., Lair S., Manie E., Raquin M.-A., Bours D., Carpentier S., Barillot E., Grill J., Doz F., Puget S., Janoueix-Lerosey I., Delattre O. Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J. Pathol. 2009, 218:86-94.
29. Ellison D.W. Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease. Acta Neuropathol. 2010, 120:305-316.
30. Thomas K.R., Capecchi M.R. Targeted disruption of the murine int-1 proto-oncogene resulting in severe abnormalities in midbrain and cerebellar development. Nature 1990, 346:847-850.
31. Pei Y., Brun S.N., Markant S.L., Lento W., Gibson P., Taketo M.M., Giovannini M., Gilbertson R.J., Wechsler-Reya R.J. WNT signaling increases proliferation and impairs differentiation of stem cells in the developing cerebellum. Development 2012, 139:1724-1733.
32. Hamilton S.R., Liu B., Parsons R.E., Papadopoulos N., Jen J., Powell S.M., Krush A.J., Berk T., Cohen Z., Tetu B., Burger P.C., Wood P.A., Taqi F., Booker S.V., Petersen G.M., Offerhaus G.J.A., Tersmette A.C., Giardiello F.M., Vogelstein B., Kinzler K.W. The molecular basis of Turcot's syndrome. N. Engl. J. Med. 1995, 332:839-847.
33. Huang H., Mahler-Araujo B.M., Sankila A., Chimelli L., Yonekawa Y., Kleihues P., Ohgaki H. APC mutations in sporadic medulloblastomas. Am. J. Pathol. 2000, 156:433-437.
34. Baeza N., Masuoka J., Kleihues P., Ohgaki H. AXIN1 mutations but not deletions in cerebellar medulloblastomas. Oncogene 2003, 22:632-636.
35. Eberhart C.G., Tihan T., Burger P.C. Nuclear localization and mutation of beta-catenin in medulloblastomas. J. Neuropathol. Exp. Neurol. 2000, 59:333-337.
36. Fuccillo M., Joyner A.L., Fishell G. Morphogen to mitogen: the multiple roles of hedgehog signalling in vertebrate neural development. Nat. Rev. Neurosci. 2006, 7:772-783.
37. Wechsler-Reya R.J., Scott M.P. Control of neuronal precursor proliferation in the cerebellum by Sonic Hedgehog. Neuron 1999, 22:103-114.
38. Gailani M.R., Bale S.J., Leffell D.J., DiGiovanna J.J., Peck G.L., Poliak S., Drum M.A., Pastakia B., McBride O.W., Kase R., et al. Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell 1992, 69:111-117.
39. Hahn H., Wicking C., Zaphiropoulous P.G., Gailani M.R., Shanley S., Chidambaram A., Vorechovsky I., Holmberg E., Unden A.B., Gillies S., Negus K., Smyth I., Pressman C., Leffell D.J., Gerrard B., Goldstein A.M., Dean M., Toftgard R., Chenevix-Trench G., Wainwright B., Bale A.E. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996, 85:841-851.
40. Oliver T.G., Read T.-A., Kessler J.D., Mehmeti A., Wells J.F., Huynh T.T.T., Lin S.M., Wechsler-Reya R.J. Loss of patched and disruption of granule cell development in a pre-neoplastic stage of medulloblastoma. Development 2005, 132:2425-2439.
41. Goodrich L.V., Milenkovic L., Higgins K.M., Scott M.P. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997, 277:1109-1113.
42. Hallahan A.R. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res. 2004, 64:7794-7800.
43. Raffel C., Jenkins R.B., Frederick L., Hebrink D., Alderete B., Fults D.W., James C.D. Sporadic medulloblastomas contain PTCH mutations. Cancer Res. 1997, 57:842-845.
44. Taylor M.D., Liu L., Raffel C., Hui C.-c., Mainprize T.G., Zhang X., Agatep R., Chiappa S., Gao L., Lowrance A., Hao A., Goldstein A.M., Stavrou T., Scherer S.W., Dura W.T., Wainwright B., Squire J.A., Rutka J.T., Hogg D. Mutations in SUFU predispose to medulloblastoma. Nat. Genet. 2002, 31:306-310.
45. Read T.A., Fogarty M.P., Markant S.L., McLendon R.E., Wei Z., Ellison D.W., Febbo P.G., Wechsler-Reya R.J. Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell 2009, 15:135-147.
46. Ward R.J., Lee L., Graham K., Satkunendran T., Yoshikawa K., Ling E., Harper L., Austin R., Nieuwenhuis E., Clarke I.D., Hui C.c., Dirks P.B. Multipotent CD15+ cancer stem cells in patched-1-deficient mouse medulloblastoma. Cancer Res. 2009, 69:4682-4690.
47. Kenney A.M., Cole M.D., Rowitch D.H. Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors. Development 2003, 130:15-28.
48. Schüller U., Heine V.M., Mao J., Kho A.T., Dillon A.K., Han Y.-G., Huillard E., Sun T., Ligon A.H., Qian Y., Ma Q., Alvarez-Buylla A., McMahon A.P., Rowitch D.H., Ligon K.L. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell 2008, 14:123-134.
49. Yang Z.-J., Ellis T., Markant S.L., Read T.-A., Kessler J.D., Bourboulas M., Schüller U., Machold R., Fishell G., Rowitch D.H., Wainwright B.J., Wechsler-Reya R.J. Medulloblastoma can be initiated by deletion of patched in lineage-restricted progenitors or stem cells. Cancer Cell 2008, 14:135-145.
50. Grammel D., Warmuth-Metz M., von Bueren A.O., Kool M., Pietsch T., Kretzschmar H.A., Rowitch D.H., Rutkowski S., Pfister S.M., Schuller U. Sonic hedgehog-associated medulloblastoma arising from the cochlear nuclei of the brainstem. Acta Neuropathol. 2012, 123:601-614.
51. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., Dirks P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63:5821-5828.
52. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., Dirks P.B. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
53. Bruggeman S.W.M., Hulsman D., Tanger E., Buckle T., Blom M., Zevenhoven J., van Tellingen O., van Lohuizen M. Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell 2007, 12:328-341.
54. Leung C., Lingbeek M., Shakhova O., Liu J. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 2004, 428:337-341.
55. Glinsky G.V., Berezovska O., Glinskii A.B. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J. Clin. Invest. 2005, 115:1503-1521.
56. Zakrzewska M., Zakrzewski K., Grešner S.M., Piaskowski S., Zalewska-Szewczyk B., Liberski P.P. Polycomb genes expression as a predictor of poor clinical outcome in children with medulloblastoma. Childs Nerv. Syst. 2010, 27:79-86.
57. Wang X., Venugopal C., Manoranjan B., McFarlane N., O'Farrell E., Nolte S., Gunnarsson T., Hollenberg R., Kwiecien J., Northcott P., Taylor M.D., Hawkins C., Singh S.K. Sonic hedgehog regulates Bmi1 in human medulloblastoma brain tumor-initiating cells. Oncogene 2012, 31:187-199.
58. Yang M.H., Hsu D.S., Wang H.W., Wang H.J., Lan H.Y., Yang W.H., Huang C.H., Kao S.Y., Tzeng C.H., Tai S.K., Chang S.Y., Lee O.K., Wu K.J. Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat. Cell Biol. 2010, 12:982-992.
59. Sutter R., Shakhova O., Bhagat H., Behesti H., Sutter C., Penkar S., Santuccione A., Bernays R., Heppner F.L., Schuller U., Grotzer M., Moch H., Schraml P., Marino S. Cerebellar stem cells act as medulloblastoma-initiating cells in a mouse model and a neural stem cell signature characterizes a subset of human medulloblastomas. Oncogene 2010, 29:1845-1856.
60. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., Martinez P., Matthews N., Stewart A., Tarpey P., Varela I., Phillimore B., Begum S., McDonald N.Q., Butler A., Jones D., Raine K., Latimer C., Santos C.R., Nohadani M., Eklund A.C., Spencer-Dene B., Clark G., Pickering L., Stamp G., Gore M., Szallasi Z., Downward J., Futreal P.A., Swanton C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 366:883-892.
61. Clarke M.F., Dick J.E., Dirks P.B., Eaves C.J., Jamieson C.H.M., Jones D.L., Visvader J., Weissman I.L., Wahl G.M. Cancer stem cells - perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006, 66:9339-9344.
62. Magee J.A., Piskounova E., Morrison S.J. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012, 21:283-296.
63. Reynolds B.A., Weiss S. Clonal and population analyses demonstrate that an EGF-responsive mammalian embryonic CNS precursor is a stem cell. Dev. Biol. 1996, 175:1-13.
64. Reynolds B.A., Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 1992, 255:1707-1710.
65. Uchida N., Buck D.W., He D., Reitsma M.J., Masek M., Phan T.V., Tsukamoto A.S., Gage F.H., Weissman I.L. Direct isolation of human central nervous system stem cells. Proc. Natl. Acad. Sci. USA 2000, 97:14720-14725.
66. Panosyan E.H., Laks D.R., Masterman-Smith M., Mottahedeh J., Yong W.H., Cloughesy T.F., Lazareff J.A., Mischel P.S., Moore T.B., Kornblum H.I. Clinical outcome in pediatric glial and embryonal brain tumors correlates with in vitro multi-passageable neurosphere formation. Pediatr. Blood Cancer 2010, 55:644-651.
67. Wu X., Northcott P.A., Dubuc A., Dupuy A.J., Shih D.J., Witt H., Croul S., Bouffet E., Fults D.W., Eberhart C.G., Garzia L., Van Meter T., Zagzag D., Jabado N., Schwartzentruber J., Majewski J., Scheetz T.E., Pfister S.M., Korshunov A., Li X.N., Scherer S.W., Cho Y.J., Akagi K., MacDonald T.J., Koster J., McCabe M.G., Sarver A.L., Collins V.P., Weiss W.A., Largaespada D.A., Collier L.S., Taylor M.D. Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature 2012, 482:529-533.
68. Beier D., Hau P., Proescholdt M., Lohmeier A., Wischhusen J., Oefner P.J., Aigner L., Brawanski A., Bogdahn U., Beier C.P. CD133+ and CD133- glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007, 67:4010-4015.
69. Clement V., Dutoit V., Marino D., Dietrich P.Y., Radovanovic I. Limits of CD133 as a marker of glioma self-renewing cells. Int. J. Cancer 2009, 125:244-248.
70. Sun Y., Kong W., Falk A., Hu J., Zhou L., Pollard S., Smith A. CD133 (Prominin) negative human neural stem cells are clonogenic and tripotent. PLoS ONE 2009, 4:e5498.
71. Abdou M., Facchino S., Chatoo W., Balasingam V., Ferreira J., Bernier G. Bmi1 sustains human glioblastoma multiforme stem cell self-renewal. J. Neurosci. 2009, 29:8884-8896.
72. Chen R., Nishimura M.C., Bumbaca S.M., Kharbanda S., Forrest W.F., Kasman I.M., Greve J.M., Soriano R.H., Gilmour L.L., Rivers C.S., Modrusan Z., Nacu S., Guerrero S., Edgar K.A., Wallin J.J., Lamszus K., Westphal M., Heim S., James C.D., VandenBerg S.R., Costello J.F., Moorefield S., Cowdrey C.J., Prados M., Phillips H.S. A hierarchy of self-renewing tumor-initating cell types in glioblastoma. Cancer Cell 2010, 17:362-375.